Marinus Pharmaceuticals (NASDAQ:MRNS) Research Coverage Started at StockNews.com

by · The Cerbat Gem

StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) in a research report released on Tuesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Marinus Pharmaceuticals Price Performance

Shares of NASDAQ:MRNS opened at $0.55 on Tuesday. The company has a market capitalization of $30.32 million, a PE ratio of -0.22 and a beta of 1.03. The business has a fifty day moving average price of $0.55 and a two-hundred day moving average price of $0.47. Marinus Pharmaceuticals has a 1 year low of $0.22 and a 1 year high of $1.97.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Virtu Financial LLC purchased a new position in shares of Marinus Pharmaceuticals during the 4th quarter valued at $36,000. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in shares of Marinus Pharmaceuticals during the 4th quarter valued at $54,000. Deltec Asset Management LLC purchased a new position in shares of Marinus Pharmaceuticals during the 4th quarter valued at $107,000. XTX Topco Ltd lifted its position in shares of Marinus Pharmaceuticals by 1,564.7% during the 4th quarter. XTX Topco Ltd now owns 219,819 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 206,614 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Marinus Pharmaceuticals by 1,968.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock worth $234,000 after purchasing an additional 126,752 shares in the last quarter. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

(Get Free Report)

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Further Reading